HRP20221295T1 - Injekcijski pripravci triterpenoidnih antifungalnih spojeva inkapsuliranih u lipozome - Google Patents
Injekcijski pripravci triterpenoidnih antifungalnih spojeva inkapsuliranih u lipozome Download PDFInfo
- Publication number
- HRP20221295T1 HRP20221295T1 HRP20221295TT HRP20221295T HRP20221295T1 HR P20221295 T1 HRP20221295 T1 HR P20221295T1 HR P20221295T T HRP20221295T T HR P20221295TT HR P20221295 T HRP20221295 T HR P20221295T HR P20221295 T1 HRP20221295 T1 HR P20221295T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- hydrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862612893P | 2018-01-02 | 2018-01-02 | |
| PCT/US2018/067216 WO2019135954A1 (en) | 2018-01-02 | 2018-12-21 | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
| EP18834263.8A EP3735226B1 (en) | 2018-01-02 | 2018-12-21 | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221295T1 true HRP20221295T1 (hr) | 2022-12-23 |
Family
ID=65024141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221295TT HRP20221295T1 (hr) | 2018-01-02 | 2018-12-21 | Injekcijski pripravci triterpenoidnih antifungalnih spojeva inkapsuliranih u lipozome |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20200338002A1 (https=) |
| EP (2) | EP4137123A1 (https=) |
| JP (3) | JP7378401B2 (https=) |
| KR (1) | KR102694692B1 (https=) |
| CN (2) | CN115998684A (https=) |
| AU (1) | AU2018399599B2 (https=) |
| CA (1) | CA3087176A1 (https=) |
| DK (1) | DK3735226T3 (https=) |
| EA (1) | EA202091626A1 (https=) |
| ES (1) | ES2927051T3 (https=) |
| HR (1) | HRP20221295T1 (https=) |
| HU (1) | HUE060400T2 (https=) |
| IL (2) | IL275758B2 (https=) |
| LT (1) | LT3735226T (https=) |
| MA (1) | MA51514A (https=) |
| MD (1) | MD3735226T2 (https=) |
| MX (1) | MX2020006992A (https=) |
| PL (1) | PL3735226T3 (https=) |
| PT (1) | PT3735226T (https=) |
| RS (1) | RS63687B1 (https=) |
| SA (1) | SA520412362B1 (https=) |
| SG (1) | SG11202006313WA (https=) |
| SI (1) | SI3735226T1 (https=) |
| SM (1) | SMT202200427T1 (https=) |
| TW (2) | TWI857944B (https=) |
| UA (1) | UA126096C2 (https=) |
| WO (1) | WO2019135954A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3087176A1 (en) * | 2018-01-02 | 2019-07-11 | Scynexis, Inc. | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| US7718189B2 (en) * | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| NZ548195A (en) * | 2004-01-14 | 2011-01-28 | Gilead Sciences Inc | Lipid-based dispersions useful for drug delivery |
| JP5245057B2 (ja) | 2006-04-03 | 2013-07-24 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗真菌剤 |
| CN101861150B (zh) * | 2007-09-28 | 2014-07-16 | 默克夏普和道赫莫公司 | 抗真菌制剂 |
| JP2011518844A (ja) * | 2008-04-25 | 2011-06-30 | ナノバイオ コーポレーション | 真菌、酵母および糸状菌感染症を治療するためのナノエマルション |
| AU2009275230A1 (en) * | 2008-07-23 | 2010-01-28 | Targeted Delivery Technologies Limited | Methods of administering topical antifungal formulations for the treatment of fungal infections |
| WO2010019204A1 (en) * | 2008-08-12 | 2010-02-18 | Merck Sharp & Dohme Corp. | Antifungal agents |
| ES2593027T3 (es) * | 2009-03-30 | 2016-12-05 | Eisai R&D Management Co., Ltd. | Composición liposomal |
| HRP20220544T1 (hr) * | 2015-01-19 | 2022-08-05 | Scynexis, Inc. | Nove soli i polimorfi scy-078 |
| CA3087176A1 (en) * | 2018-01-02 | 2019-07-11 | Scynexis, Inc. | Injectable compositions of triterpenoid antifungals encapsulated in liposomes |
-
2018
- 2018-12-21 CA CA3087176A patent/CA3087176A1/en active Pending
- 2018-12-21 MD MDE20201148T patent/MD3735226T2/ro unknown
- 2018-12-21 AU AU2018399599A patent/AU2018399599B2/en active Active
- 2018-12-21 RS RS20220981A patent/RS63687B1/sr unknown
- 2018-12-21 HU HUE18834263A patent/HUE060400T2/hu unknown
- 2018-12-21 LT LTEPPCT/US2018/067216T patent/LT3735226T/lt unknown
- 2018-12-21 CN CN202310046755.4A patent/CN115998684A/zh active Pending
- 2018-12-21 DK DK18834263.8T patent/DK3735226T3/da active
- 2018-12-21 MX MX2020006992A patent/MX2020006992A/es unknown
- 2018-12-21 UA UAA202004935A patent/UA126096C2/uk unknown
- 2018-12-21 WO PCT/US2018/067216 patent/WO2019135954A1/en not_active Ceased
- 2018-12-21 EP EP22187779.8A patent/EP4137123A1/en active Pending
- 2018-12-21 IL IL275758A patent/IL275758B2/en unknown
- 2018-12-21 SG SG11202006313WA patent/SG11202006313WA/en unknown
- 2018-12-21 EP EP18834263.8A patent/EP3735226B1/en active Active
- 2018-12-21 HR HRP20221295TT patent/HRP20221295T1/hr unknown
- 2018-12-21 ES ES18834263T patent/ES2927051T3/es active Active
- 2018-12-21 SI SI201830746T patent/SI3735226T1/sl unknown
- 2018-12-21 IL IL318793A patent/IL318793A/en unknown
- 2018-12-21 PL PL18834263.8T patent/PL3735226T3/pl unknown
- 2018-12-21 MA MA051514A patent/MA51514A/fr unknown
- 2018-12-21 US US16/958,691 patent/US20200338002A1/en not_active Abandoned
- 2018-12-21 JP JP2020536766A patent/JP7378401B2/ja active Active
- 2018-12-21 EA EA202091626A patent/EA202091626A1/ru unknown
- 2018-12-21 SM SM20220427T patent/SMT202200427T1/it unknown
- 2018-12-21 CN CN201880087851.0A patent/CN111655237B/zh active Active
- 2018-12-21 PT PT188342638T patent/PT3735226T/pt unknown
- 2018-12-21 KR KR1020207022062A patent/KR102694692B1/ko active Active
- 2018-12-27 TW TW107147395A patent/TWI857944B/zh active
- 2018-12-27 TW TW112144149A patent/TWI862280B/zh active
-
2020
- 2020-06-30 SA SA520412362A patent/SA520412362B1/ar unknown
-
2022
- 2022-10-04 US US17/960,076 patent/US20230277455A1/en not_active Abandoned
-
2023
- 2023-10-31 JP JP2023187032A patent/JP2024012452A/ja not_active Withdrawn
-
2024
- 2024-03-18 US US18/608,350 patent/US20250082574A1/en active Pending
-
2025
- 2025-04-01 JP JP2025060460A patent/JP2025106349A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100377704C (zh) | 脂质体制剂 | |
| MXPA06013886A (es) | Suspension farmaceutica inyectable que comprende posaconazol. | |
| JP2008519064A (ja) | 腹腔内投与される脂質ベースの白金化合物製剤を用いた、癌の治療方法 | |
| HRP20221295T1 (hr) | Injekcijski pripravci triterpenoidnih antifungalnih spojeva inkapsuliranih u lipozome | |
| EP2656849A1 (en) | Liposome comprising combination of chloroquine and adriamycin and preparation method thereof | |
| JP2021508728A5 (https=) | ||
| NZ765771B2 (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| JPWO2019135954A5 (https=) | ||
| US20150056269A1 (en) | Liposome comprising at least one cholesterol derivative | |
| HK40036677A (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| HK40090116A (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| HK40036677B (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| WO2025186836A1 (en) | High dosage strength of amphotericin b liposome | |
| HK40040387A (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| HK40040387B (en) | Injectable compositions of triterpenoid antifungals encapsulated in liposomes | |
| CN102631330A (zh) | 一种兰索拉唑囊泡型磷脂凝胶缓释固体制剂 |